Acurx Pharmaceuticals (ACXP)

Acurx’s platform is built around inhibition of DNA polymerase IIIC, an enzyme used by Gram-positive bacteria in DNA replication. By blocking the active site of this bacterial enzyme, the company’s drug candidates are designed to prevent bacterial replication and lead to cell death. This mechanism is distinct from many established antibiotic classes, which is important in a market where resistance can limit the usefulness of older drugs.

The company’s pipeline targets infections involving organisms such as Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, drug-resistant Streptococcus pneumoniae, and Bacillus anthracis. Its lead development focus has included oral antibiotic candidates aimed at Gram-positive infections, where a selective spectrum may help treat the pathogen while reducing unnecessary activity against unrelated bacteria.

Acurx operates as a single-segment biotechnology business, so its commercial prospects are closely linked to clinical trial results, regulatory review, manufacturing readiness, and the ability to demonstrate meaningful advantages over existing antibiotic options. ACXP offers exposure to the antimicrobial resistance theme, but like other development-stage drug companies, it carries substantial scientific, regulatory, and financing risk before any product can reach the market.